Kilic T., Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E.,
Black PM, Stiles CD. Intracranial inhibition of platelet-derived growth factor-
mediated glioblastoma cell growth by an orally active kinase inhibitor of the
2-phenylaminopyrimidine class. Cancer Res 2000;60:5143–5150.
Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the
pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49–53.
Kleinbloesem CH, van Brummelen P, Hillers J, Moolenaar AJ, Breimer DD.
Interaction between digoxin and nifedipine at steady state in patients with atrial
fibrillation. Ther Drug Monit 1985;7:372–376.
Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab
2004;5:63–84.
Kovarik JM, Purba HS, Pongowski M, Gerbeau C, Humbert H, Mueller EA.
Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1)
modulator: implications for coadministration. Pharmacotherapy 1998;18:1230–1236.
Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of
a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol
Ther 1999;66:391–400.
Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC,
Paul EM, Schellens JH. Increased oral bioavailability of topotecan in combination
with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J
Clin Oncol 2002;20:2943–2950.
Kullak-Ublick GA. Drug-induced cholestatic liver disease. Molecular Pathogenesis of
Cholestasis. Landes Bioscience, Georgetown, Tx. 2004;256–265.
Kurisu H, Kamisaka K, Koyo T, Yamasuge S, Igarashi H, Maezawa H, Uesugi T,
Tagaya O. Organic anion transport study in mutant rats with autosomal recessive
conjugated hyperbilirubinemia. Life Sci 1991;49:1003–1011.
Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically
intractable epilepsy. Epilepsia 2005;46:224–235.
Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CEAC, Keohane CA, Ly VT, Strauss
JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR. Disposition of ivermectin
and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab
Dispos 1999;27:581–587.
Lai Y, Tse C-M, Unadkat JD. Mitochondrial expression of the human equilibrative
nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of
antiviral drugs. J Biol Chem 2004;279:4490–4497.
Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a
subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol
Appl Pharmacol 1997;143:357–365.
Lau YY, Wu C-Y, Okochi H, Benet LZ.Ex situinhibition of hepatic uptake and efflux
significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol
Exp Ther 2004;308:1040–1045.
Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of
atorvastatin and its two active hydroxy metabolites: application ofin vitroandex situ
systems. J Pharmacol Exp Ther 2006;316:762–771.
Lee E-W, Lai Y, Zhang H, Unadkat JD. Identification of the mitochondrial targeting
signal of the human equilibrative nucleoside transporter 1 (hENT1): implications
192 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS